Actuate Therapeutics Inc (ACTU)
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies in the United States. Its lead candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is being evaluated in a Phase 2 study for metastatic pancreatic ductal adenocarcinoma. The company is also studying elraglusib in a Phase 1/2 trial for refractory pediatric malignancies, including Ewing sarcoma, neuroblastoma, and pediatric leukemias. Founded in 2015 and headquartered in Fort Worth, Texas, the company was previously known as Apotheca Therapeutics, Inc. before adopting its current name in October 2015.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ACTU
|
$1.48
|
8.8% Upside
|
Fair
|
$9.98
|
633.6% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 2, 2026
|
-1.5x
|
8.7x
|
—
|
33.496 M
|
24.644 M
|
0.0%
|
35.8%
|
-28.8
|
—
|
91.0%
|
